References
- 1. Jagiełło-Gruszfeld A, Pogoda K, Kłak A, Stróżek J. Zalecenia dla polityki państwa w zakresie zaawansowanego raka piersi. Warszawa: Instytut Ochrony Zdrowia; 2017.
- 2. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;3:1194-220.10.1093/annonc/mdz17331161190
- 3. Helvie MA, Bevers TB. Screening mammography for average-risk women: The controversy and NCCN’s position. J Natl Compr Canc Netw. 2018;16:1398-404.10.6004/jnccn.2018.708130442738
- 4. Gøtzsche PC. Mammography screening is harmful and should be abandoned. J R Soc Med. 2015;108:341-5.10.1177/0141076815602452458226426359135
- 5. Cancer Screening in the European Union 2017. Report on the implementation of the Council Recommendation on cancer screening. International Agency for Research on Cancer Lyon, France; 2017.
- 6. Patel BK, Lobbes MBI, Lewin J. Contrast enhanced spectral mammography: A review. Semin Ultrasound CT MR. 2018;39:70-9.10.1053/j.sult.2017.08.00529317041
- 7. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27:v103-v110. (Erratum in: Ann Oncol. 2017 Jul 1;28(suppl_4):iv167-iv168. PMID: 27664246)10.1093/annonc/mdw327
- 8. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8-30.10.1093/annonc/mdv298
- 9. D’Orsi CJ, Getty DJ, Pickett RM, Sechopoulos I, Newell MS, Gundry KR, et al. Stereoscopic digital mammography: improved specificity and reduced rate of recall in a prospective clinical trial. Radiology. 2013;266:81-8.10.1148/radiol.1212038223150865
- 10. Spak DA, Plaxco JS, Santiago L, Dryden MJ, Dogan BE. BI-RADS® fifth edition: A summary of changes. Diagn Interv Imaging. 2017;98:179-90.10.1016/j.diii.2017.01.00128131457
- 11. Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol. 2019;21:1-10.10.1007/s11307-018-1181-329516387
- 12. Jassem J. Krzakowski M. Rak piersi. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Onkol Prakt Klin Edu. 2018;4:209-56.
- 13. Bick U, Trimboli RM, Athanasiou A, Balleyguier C, Baltzer PAT, Bernathova M, et al. European Society of Breast Imaging (EUSOBI), with language review by Europa Donna – The European Breast Cancer Coalition. Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging. 2020;11:12.10.1186/s13244-019-0803-x700262932025985
- 14. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC cancer staging manual: Breast cancer. Ann Surg Oncol. 2018;25:1783-5.10.1245/s10434-018-6486-629671136
- 15. Chen S, Liang Y, Feng Z, Wang M. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:973.10.1186/s12885-019-6132-0680534631638935